In a game-changing move for the biotechnology and personalized medicine sector, Regeneron Pharmaceuticals, Inc. has gained approval for Dupixent (dupilumab) as the single targeted treatment for patients with bullous pemphigoid (BP). This marks a significant stride in managing this challenging autoimmune disorder, spotlighting the potential of targeted therapies to revolutionize the treatment landscape. Bullous pemphigoid […]
